



*Fondazione Ricerca
Fibrosi Cistica - ETS
italian cystic fibrosis research foundation*

23RD CONVENTION of investigators in cystic fibrosis

13-15 November 2025

Camera di Commercio, Corso Porta Nuova 96 - Verona

FULL PROGRAM

Piazzale Stefani 1 | c/o Azienda Ospedaliera Universitaria Integrata | 37126 Verona
Codice fiscale 93100600233 | fondazione.ricercafc@aovr.veneto.it | Tel 045 812 3438
fibrosicisticaricerca.it

Thursday, 13 November 2025

	09:30 - 10:30	Registration and poster display
	10:30 – 11:30	Introduction and greetings Matteo Marzotto (President FFC Ricerca) Antonio Guarini (President LIFC Lega Italiana Fibrosi Cistica) Callisto Marco Bravi (Director AOUI Verona) Carlo Castellani (Scientific director FFC Ricerca) Francesco Blasi (President SIFC Società Italiana Fibrosi Cistica) Cecilia Cascone (Representative Consultation group FFC Ricerca)
	11:30 – 11:40	Introduction to the 23rd Convention of FFC Ricerca Carlo Castellani (Scientific director FFC Ricerca)

	11:40 – 13:00 SESSION 1	THE MULTIFACETED KAFTRIO Chair: Carlo Castellani, Cristina Cigana
		1. Maria Cristina Lucanto, Cesare Braggion, Cristina Cigana, Nicoletta Pedemonte (Kaftrio in the real life) Efficacy and safety of Kaftrio in real life: an observational multicenter Italian clinical study (10') 2. Lucilla Nobbio, Andrea Armirotti (FFC#2/2024) Investigating the safety of elexacaftor/tezacaftor/ivacaftor (ETI) exposure during pregnancy and early development (10') 3. Santiago Ramòn-Garcia (FFC#9/2024) Understanding the contribution of Kaftrio to antimicrobial therapies against nontuberculous mycobacteria in cystic fibrosis (10') 4. Sonia Graziano, Alexandra Quittner, Rita Pescini, Cristiana Risso, Angela Sepe, Vito Terlizzi (MindKids-CF) Survey on Mental Health in Children with Cystic Fibrosis (15') 5. Alberto Battezzati, Federico Alghisi, Stefano Costa (FFC#14/2024) Long-term clinical outcomes of insulin secretory defects and effects of CFTR modulators (10')
	12:35 – 13:00	Discussion

	13:00 – 14:30	Lunch
--	---------------	-------

	14:30 – 16:30 SESSION 2	MODULATORS AND GENETIC THERAPIES Chair: Marco Cipolli, Tiziano Bandiera
		6. Giovanni Marzaro, Gergely Lukacs, Tamas Hegedus (FFC#1/2024) Development of new potentiators active on (ultra)rare mutants of

		CFTR (10') 7. Mauro Salvi (FFC#3/2024) Promoting correct folding to enhance F508del-CFTR rescue induced by correctors (20') 8. Carlos M. Farinha, Valeria Tomati (FFC#2/2023) Exploring the cellular pathways to promote rescue of mutant CFTR protein in cystic fibrosis (10') 9. Paola Barraja, Luis J. V. Galletta (Molecules 3.0 for CF) Optimization and <i>in vivo</i> testing of two new classes of modulators and pharmacokinetic studies (15') 10. Giulia Maule (MSG#1/2022) Development of CRISPR-Cas delivery system for genome editing applications in cystic fibrosis (20') 11. Anna Cereseto, Sven Even Borgos, Luis J.V. Galletta, Sheref Mansy, Serena Zacchigna (GenDel-CF) Tackling gene delivery in lungs for the treatment of cystic fibrosis (15')
	16:00 - 16:30	Discussion

	16:30 - 17:45	Coffee Break and poster session A
--	---------------	-----------------------------------

	17:45 – 18:30 SPECIAL LECTURE	CFTR in the Kidney: Physiology and Clinical Implications Peder Berg (45')
--	---	---

Friday, 14 November 2025

	9:00 - 10:20 SESSION 3	HOT INFLAMMATION TOPICS Chair: Maria Cristina Lucanto, Giulio Cabrini
		12. Ilaria Lampronti, Adriana Chilin (FFC#11/2024) GY971 as anti-inflammatory agent 2.0 (10') 13. Domenico Mattoscio (FFC#12/2024) Targeting immune system to restrain cystic fibrosis airway inflammation (10') 14. Antonio Recchiuti (FFC#13/2024) Unraveling proresolving effects of CFTR modulators on lung inflammation and infection (10') 15. Mario Romano, Mauro Perretti (FFC#15/2023) Melanocortins to control cystic fibrosis airway inflammation (10') 16. Daniela Guidone (GMRF#1/2024) Airway surface as a battleground against bacteria (10') 17. Onofrio Laselva, Valeria Capurro, Enza Montemitro (FFC#4/2024)

		A personalized repurposing approach based on antiinflammatory/ antioxidant treatment to increase the efficacy of CFTR modulators (10') 18. Giulio Cabrini, Marco Prosdocimi, Sjoerd Hak, Ilaria Lampronti, Adriana Chilin, Alessandra Bragonzi, Nicoletta Pedemonte New strategic project FFC Ricerca (10')
	10:10 - 10:30	Discussion

	10:30 - 11:00	Coffee Break
--	---------------	--------------

	11:00 - 12:30 SESSION 4	THE NTM CHALLENGE Chair: Sonia Volpi, Alessandra Bragonzi
		19. Maria Rosalia Pasca, Fabio Saliu (FFC#9/2023 + FFC#11/2025) Evaluation of the efficacy of the VOMG new antibiotic against <i>Mycobacterium abscessus</i> (20') 20. Nicola Ivan Lorè, Lisa Cariani (FFC#7/2022 + FFC#12/2025) Genomic and phenotypic characterization of <i>Mycobacterium abscessus</i> and detection of host biomarkers to define mycobacterial infection in cystic fibrosis (20') 21. Edoardo Scarpa, Daniela Maria Cirillo (FFC#12/2023) Fostering pathogen host-mediated clearance to neutralize <i>Mycobacterium abscessus</i> infection (20') 22. Stefano Sabatini, Laura Rindi (FFC#10/2024) Phenotypic medicinal chemistry approaches to identify new anti-<i>Mycobacterium abscessus</i> agents (10')
	12:10 - 12:30	Discussion

	12:30 - 13:15 SESSION 5	FLASH PRESENTATION: FACILITIES AND NEW PROJECTS Chair: Ermanno Rizzi
		23. Alessandra Bragonzi CFaCore, The cystic fibrosis animal core (3') 24. Roberto Buzzetti, Natalia Cirilli CFDB, The cystic fibrosis database (3') 25. Valeria Capurro SCP, The primary cultures facility (3') 26. Margarida Amaral, Ines Pankonien, Emanuela Pesce, Emanuel Gonçalves (FFC#1/2025) Damage and repair mechanisms in epithelial tissues in cystic fibrosis (3') 27. Debora Baroni (FFC#2/2025) An antisense oligonucleotide-based strategy for the rescue of CFTR stop and splicing mutations (3') 28. Marianne Carlon, Anna Cereseto (FFC#3/2025)

		Optimizing gene therapy and delivery systems for CF untreatable mutations (3') 29. Luis J. V. Galletta (FFC#4/2025) Pharmacological approaches to target nonsense mutations in cystic fibrosis (3') 30. Emilio Hirsch (FFC#5/2025) Characterization of protein kinase D1 as a novel regulator of CFTR trafficking and stability (3') 31. Maria Luisa Mangoni, Loretta Ferrera, Mattia Mori (FFC#6/2025) Exploring the dual function of Esc peptides and their derivatives as CFTR potentiators and antimicrobial agents (3') 32. Marta Mellini (GMSG#1/2025) Unconventional approaches to combat cystic fibrosis bacteria (3') 33. Andrea Battistoni, Luigi Scipione (FFC#7/2025) Exploiting <i>P. aeruginosa</i>'s zinc dependency to potentiate antibiotic activity (3') 34. Maurizio Fraziano, Daniela Maria Cirillo (FFC#8/2025) Development of a combined therapy with bioactive liposomes encapsulating antibiotics to treat <i>M. abscessus</i> infection (3') 35. Federico Giannoni, Riccardo Manganelli (FFC#9/2025) Identification of novel drug targets in persistent <i>Mycobacterium abscessus</i> in cystic fibrosis (3') 36. Francesco Imperi, Giorgio Giardina, Antonio Coluccia (FFC#10/2025) Targeting <i>Pseudomonas aeruginosa</i> virulence factors to counteract infections in cystic fibrosis (3') 37. Cristina Cigana, Valeria Daccò, Barbara Kahl (FFC#13/2025) Tracking lung infections via gut microbiota (3')
--	--	--

	13:15 – 13:30	GROUP PHOTO AT AUDITORIUM
--	---------------	---------------------------

	13:30 – 15:20	Lunch and Poster Session B
--	---------------	----------------------------

	15:20 - 16:10 SESSION 6	PHAGES AND FUNGI Chair: Elio Castagnola, Emilio Clementi
		38. Mariagrazia Di Luca, Laura Rindi, Andrea Moscatelli (FFC#6/2024) Development of phage therapy for treating <i>Mycobacterium abscessus</i> lung infections in people with cystic fibrosis (10') 39. Federica Briani (FFC#16/2023) Facing resistance to therapeutic phages observed in <i>Pseudomonas aeruginosa</i> isolates from people with cystic fibrosis (10') 40. Marco Cafora (GMRF#1/2023) <i>Ex vivo</i> pig lung as a new model to study the efficacy of phage therapy against <i>Pseudomonas aeruginosa</i> infection in cystic fibrosis

		(10') 41. Teresa Zelante (FFC#15/2022) Study on anti-fungal immunoglobulins, as a potential diagnostic biomarker and therapeutic values for Allergic Bronchopulmonary Aspergillosis in children with cystic fibrosis (20')
	16:10 - 16:30	Discussion

	16:30 – 17:15 SPECIAL LECTURE	TITLE TBD David Sheppard (45')
--	---	-----------------------------------

	20:00	SOCIAL DINNER at Palazzo Verità Poeta - Vicolo San Silvestro 6, Verona
--	-------	---

Saturday, 15 November 2024

	9:00 - 11:00 SESSION 7	TACKLING PSEUDOMONAS AERUGINOSA Chair: Giovanni Taccetti, Alessandra Bragonzi
		42. Giovanni Bertoni, Silvia Ferrara (FFC#5/2024) Targeting bacterial small RNA to develop non-traditional therapeutic options against <i>Pseudomonas aeruginosa</i> (10') 43. Sandra Gemma, Arianna Pompilio (FFC#7/2024) Targeting quorum sensing to fight <i>Pseudomonas aeruginosa</i> infections (10') 44. Annalisa Guaragna, Eliana De Gregorio (FFC#8/2024) A combined therapy against <i>Pseudomonas aeruginosa</i>-<i>Staphylococcus aureus</i> co-infections in cystic fibrosis (10') 45. Martina Rossitto, Marco Artini (FFC#15/2024) Analysis of the evolution of virulence factors and antimicrobial resistance of <i>Pseudomonas aeruginosa</i> in people with cystic fibrosis (10') 46. Silvia Buroni, Antonio Coluccia (FFC#6/2023) Using a Virtual Screening approach to find new drugs against <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i> (10') 47. Barbara Citterio, Massimiliano Lucidi (FFC#7/2023) Evaluation of cefiderocol activity against <i>Pseudomonas aeruginosa</i> in cystic fibrosis lung infections (20') 48. Eugenio Notomista, Ivana D'Angelo (FFC#8/2023) Inhalable nanoparticles delivering peptidomimetic/antibiotic combinations for local treatment of CF lung infections (20') 49. Marco Sette, Mattia Falconi, Marco Rinaldo Oggioni (FFC#13/2023) Building simple molecules containing regions of <i>Pseudomonas</i>

		<i>aeruginosa</i> to stimulate the immune system against this pathogen (10')
	10:40 - 11:00	Discussion

	11:00 – 11:30	Coffee Break
--	---------------	--------------

	11:30 - 12:40 SESSION 8	DIFFERENT CHALLENGES, DIFFERENT APPROACHES Chair: Cesare Braggion, Nicoletta Pedemonte
		50. Renata Bocciardi (FFC#3/2023) Understanding the mechanisms behind the variable efficacy of CFTR modulators on the N1303K mutation on human primary nasal epithelial cells (10') 51. Roberto Plebani (GMSG#1/2023) Developing a new respiratory 3D model as an innovative strategy to study the inflammation pathology in cystic fibrosis (10') 52. Michele Genovese (GMSG#1/2024) Alternative therapeutic target to restore the mucociliary clearance in CF (10') 53. Moira Paroni, Clelia Peano (FFC#14/2023) Identification of molecular mechanisms which underpin the activation of pathogenic pulmonary Th1/17 cells in cystic fibrosis (10') 54. Alessandra Bragonzi, Federica Ungaro, Valeria Daccò (FFC#5/2023) Beyond the lung: the gut's role in the pathology of cystic fibrosis (10')
	12:20 - 12:40	Discussion

	12:40 - 12:55	Closing remarks
--	---------------	-----------------

	12:55 – 13:15	Poster detachment
--	---------------	-------------------